Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian I Rini

Showing results (111-120 of 401) with videos related to

Pageof 41
Sort By:
Nature Reviews. Nephrology|August 1, 2020
The immunology of renal cell carcinomaC Marcela Díaz-Montero, Brian I Rini, James H Finke
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
The Evolution of Systemic Therapy in Metastatic Renal Cell CarcinomaThomas E Hutson, Gregory R Thoreson, Robert A Figlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Prostate cancer immunology: biology, therapeutics, and challengesW Scott Webster, Eric J Small, Brian I Rini, et al.
Urology|February 3, 2007
Targeted molecular therapy for renal cell carcinomaBrian R Lane, Brian I Rini, Andrew C Novick, et al.
The Journal of Urology|May 16, 2006
Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factorBrian I Rini, Lawrence Fong, Vivian Weinberg, et al.
Cancer|February 14, 2015
Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Susan Halabi, Brian I Rini, Bernard Escudier, et al.
JAMA Oncology|March 27, 2025
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A ReviewGiulia Claire Giudice, Kathryn E Beckermann, Paulo Siqueira Do Amaral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaBrian I Rini, Susan Halabi, John Taylor, et al.
Clinical Genitourinary Cancer|January 24, 2007
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastasesBrian I Rini, Vanessa Shaw, Jonathan E Rosenberg, et al.
Clinical Pharmacokinetics|October 26, 2014
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinomaYing Chen, Brian I Rini, Angel H Bair, et al.
Pageof 41

Showing results (111-120 of 401) with videos related to

Sort By:
Pageof 41
Nature Reviews. Nephrology|August 1, 2020
The immunology of renal cell carcinomaC Marcela Díaz-Montero, Brian I Rini, James H Finke
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
The Evolution of Systemic Therapy in Metastatic Renal Cell CarcinomaThomas E Hutson, Gregory R Thoreson, Robert A Figlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Prostate cancer immunology: biology, therapeutics, and challengesW Scott Webster, Eric J Small, Brian I Rini, et al.
Urology|February 3, 2007
Targeted molecular therapy for renal cell carcinomaBrian R Lane, Brian I Rini, Andrew C Novick, et al.
The Journal of Urology|May 16, 2006
Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factorBrian I Rini, Lawrence Fong, Vivian Weinberg, et al.
Cancer|February 14, 2015
Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Susan Halabi, Brian I Rini, Bernard Escudier, et al.
JAMA Oncology|March 27, 2025
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma: A ReviewGiulia Claire Giudice, Kathryn E Beckermann, Paulo Siqueira Do Amaral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaBrian I Rini, Susan Halabi, John Taylor, et al.
Clinical Genitourinary Cancer|January 24, 2007
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastasesBrian I Rini, Vanessa Shaw, Jonathan E Rosenberg, et al.
Clinical Pharmacokinetics|October 26, 2014
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinomaYing Chen, Brian I Rini, Angel H Bair, et al.
Pageof 41